Debt-free Balance SheetArcoma's reduction of total debt to effectively zero materially improves financial flexibility and reduces solvency and interest-rate risk. Over 2–6 months this supports funding for product support, modest capex or targeted M&A without reliance on external financing, improving resilience.

Strong Cash GenerationConsistent positive operating cash flow and a pronounced free cash flow pickup in 2025 indicate improved cash conversion and internal funding capacity. This durable cash generation can underwrite R&D, service operations and working capital needs while lowering refinancing risk over the medium term.

Profitability TurnaroundTransitioning from losses to sustained positive EBIT and net income shows structural operational improvement. Improved profitability supports reinvestment in product development and service delivery, and, if maintained, can drive stronger returns and stability in free cash flow over the coming months.

Bears Say

Weakening Revenue TrendFalling revenue in consecutive years undermines long-term durability: it pressures margins, limits scale benefits, and may signal weakening demand or competitive pressure in the imaging market. Sustained top-line declines would erode recent cash improvements without a clear recovery plan.

2025 Gross Profit CompressionA sharp gross profit decline in 2025 despite similar revenue points to cost or pricing pressure rather than volume. That structural margin erosion threatens long-term profitability and free cash flow sustainability unless cost base or pricing power is restored, increasing execution risk.

Small Scale And Volatile ReturnsWith only ~31 employees and historically volatile ROE, Arcoma's small scale magnifies execution and revenue-concentration risks. Variable returns indicate earnings sensitivity to a few contracts or cost swings, making durable margin and growth consistency harder to rely on over the medium term.

ARCOMA FAQ

What was Arcoma AB’s price range in the past 12 months?

Arcoma AB lowest stock price was kr6.16 and its highest was kr11.00 in the past 12 months.

What is Arcoma AB’s market cap?

Arcoma AB’s market cap is kr121.62M.

When is Arcoma AB’s upcoming earnings report date?

Arcoma AB’s upcoming earnings report date is Apr 23, 2026 which is in 51 days.

How were Arcoma AB’s earnings last quarter?

Arcoma AB released its earnings results on Feb 12, 2026. The company reported kr0.1 earnings per share for the quarter, missing the consensus estimate of kr0.17 by -kr0.07.

Is Arcoma AB overvalued?

According to Wall Street analysts Arcoma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arcoma AB pay dividends?

Arcoma AB does not currently pay dividends.

What is Arcoma AB’s EPS estimate?

Arcoma AB’s EPS estimate is 0.18.

How many shares outstanding does Arcoma AB have?

Arcoma AB has 14,308,510 shares outstanding.

What happened to Arcoma AB’s price movement after its last earnings report?

Arcoma AB reported an EPS of kr0.1 in its last earnings report, missing expectations of kr0.17. Following the earnings report the stock price went down -1.939%.

Which hedge fund is a major shareholder of Arcoma AB?

Currently, no hedge funds are holding shares in SE:ARCOMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Arcoma AB

Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners. Arcoma AB was founded in 1990 and is based in Växjö, Sweden.